Morgan Stanley Rocket Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 3,169,036 shares of RCKT stock, worth $9.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,169,036

Previous 2,641,892 19.95%

Holding current value

$9.22 Million

Previous $17.6 Million 55.94%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$2.33 - $8.01 $1.23 Million - $4.22 Million	527,144 Added 19.95%	3,169,036 $7.76 Million
Q1 2025 May 15, 2025	BUY	$6.67 - $12.72 $9.72 Million - $18.5 Million	1,457,183 Added 123.0%	2,641,892 $17.6 Million
Q4 2024 Feb 14, 2025	BUY	$11.35 - $18.82 $6.46 Million - $10.7 Million	569,181 Added 92.47%	1,184,709 $14.9 Million
Q3 2024 May 14, 2025	BUY	$17.6 - $25.88 $2.46 Million - $3.61 Million	139,540 Added 29.32%	615,528 $11.4 Million
Q3 2024 Nov 14, 2024	BUY	$17.6 - $25.88 $2.46 Million - $3.61 Million	139,540 Added 29.32%	615,528 $11.4 Million
Q2 2024 May 14, 2025	SELL	$20.66 - $26.72 $14.6 Million - $18.9 Million	-708,721 Reduced 59.82%	475,988 $10.2 Million
Q2 2024 Oct 17, 2024	SELL	$20.66 - $26.72 $4.4 Million - $5.69 Million	-212,825 Reduced 30.9%	475,988 $10.2 Million
Q2 2024 Aug 14, 2024	SELL	$20.66 - $26.72 $4.4 Million - $5.69 Million	-212,825 Reduced 30.9%	475,988 $10.2 Million
Q1 2024 Oct 17, 2024	BUY	$26.16 - $30.74 $5.57 Million - $6.54 Million	212,825 Added 44.71%	688,813 $18.6 Million
Q1 2024 Aug 16, 2024	BUY	$26.16 - $30.74 $2.01 Million - $2.36 Million	76,840 Added 12.56%	688,813 $18.6 Million
Q1 2024 May 15, 2024	BUY	$26.16 - $30.74 $2.01 Million - $2.36 Million	76,840 Added 12.56%	688,813 $18.6 Million
Q4 2023 Aug 16, 2024	BUY	$16.78 - $31.94 $2.28 Million - $4.34 Million	135,985 Added 28.57%	611,973 $18.3 Million
Q4 2023 Feb 13, 2024	SELL	$16.78 - $31.94 $2.8 Million - $5.33 Million	-166,778 Reduced 21.42%	611,973 $18.3 Million
Q3 2023 Nov 15, 2023	BUY	$15.07 - $24.05 $4.17 Million - $6.65 Million	276,627 Added 55.09%	778,751 $16 Million
Q2 2023 Aug 14, 2023	SELL	$16.59 - $23.6 $1.49 Million - $2.12 Million	-89,902 Reduced 15.19%	502,124 $9.98 Million
Q1 2023 May 15, 2023	BUY	$15.79 - $22.6 $910,672 - $1.3 Million	57,674 Added 10.79%	592,026 $10.1 Million
Q4 2022 Feb 14, 2023	SELL	$15.5 - $22.76 $10.3 Million - $15.1 Million	-661,733 Reduced 55.32%	534,352 $10.5 Million
Q3 2022 Nov 14, 2022	SELL	$12.37 - $18.41 $1.08 Million - $1.6 Million	-86,914 Reduced 6.77%	1,196,085 $19.1 Million
Q2 2022 Oct 27, 2022	SELL	$7.96 - $16.64 $1.62 Million - $3.39 Million	-203,689 Reduced 13.7%	1,282,999 $17.7 Million
Q2 2022 Aug 15, 2022	SELL	$7.96 - $16.64 $1.62 Million - $3.39 Million	-203,689 Reduced 13.7%	1,282,999 $17.7 Million
Q1 2022 Oct 27, 2022	BUY	$13.16 - $23.68 $2.68 Million - $4.82 Million	203,689 Added 15.88%	1,486,688 $23.6 Million
Q1 2022 May 13, 2022	BUY	$13.16 - $23.68 $3.77 Million - $6.79 Million	286,807 Added 23.9%	1,486,688 $23.6 Million
Q4 2021 Feb 14, 2022	BUY	$21.52 - $36.02 $22.3 Million - $37.4 Million	1,036,981 Added 636.58%	1,199,881 $26.2 Million
Q3 2021 Nov 15, 2021	BUY	$27.42 - $48.97 $4.47 Million - $7.98 Million	162,900 New	162,900 $4.87 Million

Others Institutions Holding RCKT

# of Institutions

220

Shares Held

98.3M

Call Options Held

611K

Put Options Held

487K

View Full List

About ROCKET PHARMACEUTICALS, INC.

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $220M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

More about RCKT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account